Overview

Study of Salmeterol (SN408D) for Adult Asthma

Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
To demonstrate the efficacy (non-inferiority) of Salmeterol 50mcg bid (100mcg/day), compared with Hokunalin (tulobuterol) tape 2mg once a day, in terms of improvement in pulmonary function (peak expiratory flow: PEF) in a randomized, double-blind, parallel-group comparative study in adult patients with bronchial asthma on ICS 400mcg/day of FP equivalent.
Phase:
Phase 4
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Salmeterol Xinafoate
Terbutaline
Tulobuterol